Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 16/20 | 0.95 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14986997 | 0.98 | GLS (1.00) | GLSMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL14987142 | 0.90 | GLS (1.00) | GLSMAPTALDH1A1LMNA | |
| SCHEMBL18121472 | 0.87 | GLS (0.80) | GLSMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL14987419 | 0.79 | GLS (1.00) | GLSMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL21368901 | 0.79 | GLS (0.77) | GLSMAPTALDH1A1 | |
| SCHEMBL14987271 | 0.77 | GLS (1.00) | GLSMAPTALDH1A1 | |
| SCHEMBL14987003 | 0.75 | GLS (1.00) | GLSMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL14987270 | 0.74 | GLS (1.00) | GLSMAPT | |
| SCHEMBL19550411 | 0.72 | GLS (0.55) | GLSALDH1A1 | |
| SCHEMBL19550961 | 0.72 | GLS (0.55) | GLSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150258082-A1 | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258082-A1 | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS | GLS, GLUL, GLS2 | GLS 1/4885MAPT 4563/4885ALDH1A1 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.